Pfizer (PFE)

Shares popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.

These companies' shares have fallen too far, offering investors an attractive opportunity.

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the beginning of a high-stakes pivot toward oncology. The German biotech pioneer recorded a net loss of €1.1 billion

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering "hangover" period in 2023 and 2024, the pharmaceutical giant is currently in the middle of a high-stakes transformation. The company is attempting to [...]

As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq: XENE). Long a favorite of biotech specialists for its deep expertise in ion-channel biology, Xenon has officially transitioned from a "high-potential" R&D firm to a "pre-commercial" titan following [...]

A handful of the industry's income-generating gems are hiding in plain sight.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

The company incurred a loss in its most recent quarterly results.

AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.

It delivered for shareholders in its fourth quarter of 2025 with a double beat on analyst projections.

Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

Amarin is milking a cash cow, but it looks like that cow is slowly being bled to death.

Regencell Bioscience doesn't have a product yet, and there's no indication that one is on the way.

President Trump's tariffs have been overturned, throwing the market into even more chaos in 2026.

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a household name during the COVID-19 pandemic, this latest rally signals a critical maturation point. Investors are no longer valuing Moderna solely on its [...]

China approves ecnoglutide weight-loss injection linked to Pfizer after trial shows up to 15.4% average weight reduction in adults.

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant Sciences and Arbutus Biopharma (NASDAQ:ABUS). Announced on March 3, 2026, the deal concludes one of the most contentious patent

Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level of investor enthusiasm not seen since the peak of the pandemic. While the broader markets remained relatively flat, Moderna’s spike was fueled by a convergence of positive clinical [...]

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.

Rising geopolitical tensions, surging oil prices, and increasing volatility are pressuring U.S. equities and driving a shift toward defensive positioning.

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Explore how portfolio risk, bond type, and diversification set these two fixed income ETFs apart for different investor priorities.